Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,826 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
CYP2C19*17 is associated with decreased breast cancer risk.
Justenhoven C, Hamann U, Pierl CB, Baisch C, Harth V, Rabstein S, Spickenheuer A, Pesch B, Brüning T, Winter S, Ko YD, Brauch H. Justenhoven C, et al. Among authors: winter s. Breast Cancer Res Treat. 2009 May;115(2):391-6. doi: 10.1007/s10549-008-0076-4. Epub 2008 Jun 3. Breast Cancer Res Treat. 2009. PMID: 18521743
Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen.
Schroth W, Goetz MP, Hamann U, Fasching PA, Schmidt M, Winter S, Fritz P, Simon W, Suman VJ, Ames MM, Safgren SL, Kuffel MJ, Ulmer HU, Boländer J, Strick R, Beckmann MW, Koelbl H, Weinshilboum RM, Ingle JN, Eichelbaum M, Schwab M, Brauch H. Schroth W, et al. Among authors: winter s. JAMA. 2009 Oct 7;302(13):1429-36. doi: 10.1001/jama.2009.1420. JAMA. 2009. PMID: 19809024 Free PMC article.
Polymorphisms of the nuclear receptor pregnane X receptor and organic anion transporter polypeptides 1A2, 1B1, 1B3, and 2B1 are not associated with breast cancer risk.
Justenhoven C, Schaeffeler E, Winter S, Baisch C, Hamann U, Harth V, Rabstein S, Spickenheuer A, Pesch B, Brüning T, Ko YD, Schwab M, Brauch H. Justenhoven C, et al. Among authors: winter s. Breast Cancer Res Treat. 2011 Jan;125(2):563-9. doi: 10.1007/s10549-010-1046-1. Epub 2010 Jul 16. Breast Cancer Res Treat. 2011. PMID: 20635135
The postmenopausal hormone replacement therapy-related breast cancer risk is decreased in women carrying the CYP2C19*17 variant.
Justenhoven C, Obazee O, Winter S, Couch FJ, Olson JE, Hall P, Hannelius U, Li J, Humphreys K, Severi G, Giles G, Southey M, Baglietto L, Fasching PA, Beckmann MW, Ekici AB, Hamann U, Baisch C, Harth V, Rabstein S, Lotz A, Pesch B, Brüning T, Ko YD, Brauch H. Justenhoven C, et al. Among authors: winter s. Breast Cancer Res Treat. 2012 Jan;131(1):347-50. doi: 10.1007/s10549-011-1827-1. Epub 2011 Oct 26. Breast Cancer Res Treat. 2012. PMID: 22037784 No abstract available.
Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters.
Brauch H, Schroth W, Goetz MP, Mürdter TE, Winter S, Ingle JN, Schwab M, Eichelbaum M. Brauch H, et al. Among authors: winter s. J Clin Oncol. 2013 Jan 10;31(2):176-80. doi: 10.1200/JCO.2012.44.6625. Epub 2012 Oct 22. J Clin Oncol. 2013. PMID: 23091108 Free PMC article. No abstract available.
1,826 results